Abstract DESTINY-CRC01 (NCT03384940) was a multicentre. open-label. phase 2 study that investigated the safety and efficacy of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing metastatic colorectal cancer (CRC). The present exploratory biomarker analysis aims to investigate relationships between biomarkers and clinical outcomes... https://www.ceomelinh.com/product-category/delaware/